CRMD

Cormedix

• Seeking Alpha·3h ago

  CorMedix: A Shrinking Core And No Proven Second Engine

• Reuters·19h ago

  CorMedix to join Needham Virtual Healthcare Conference fireside chat and investor meetings

• Seeking Alpha·5d ago

  CorMedix: Waiting On Phase III ReSPECT For A Further Re-Rating (Upgrade)

• TipRanks·03/11 00:08

  Cormedix Earnings Call: Peak DEFENCATH, Tough Road Ahead

• TipRanks·03/06 22:30

  CorMedix Reaffirms DefenCath 2027 Sales and Outlook

• TipRanks·03/06 22:20

  CorMedix affirms FY26 revenue view of $300M-$320M, consensus $308.7M

• TipRanks·03/06 17:05

  CorMedix price target lowered to $13 from $15 at Leerink

• TipRanks·03/06 13:40

  Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX), Altimmune (ALT) and Cormedix (CRMD)

• TipRanks·03/06 12:37

  Cormedix (CRMD) Receives a Buy from RBC Capital

• Dow Jones·03/06 10:59

  CorMedix Price Target Cut to $14.00/Share From $15.00 by Needham

• Dow Jones·03/06 10:59

  CorMedix Is Maintained at Buy by Needham

• NASDAQ·03/06 07:25

  CorMedix Q4 Revenue Improves; Reaffirms FY26 Outlook; Plans To Report Phase III REZZAYO Data In Q2

• TipRanks·03/05 20:25

  Buy Rating Maintained as Long-Term Rezzayo Upside Remains Underappreciated Despite Near-Term Weakness

• Seeking Alpha·03/05 19:56

  CorMedix outlines $300M–$320M revenue and $100M–$125M EBITDA targets for 2026 amid DefenCath transition and Melinta integration

• TipRanks·03/05 16:30

  Analysts’ Opinions Are Mixed on These Healthcare Stocks: Altimmune (ALT), Rhythm Pharmaceuticals (RYTM) and Cormedix (CRMD)